Subject
Neurology (clinical),Neurology,General Medicine
Reference43 articles.
1. Adam Czaplinski, F.M., Petra Stellmes, Simon Ramseier, Lutz Achtnichts, Andreas Baumann, Oleg Kurlandchikov, Christian Berger, Michael Chofflon, Alla L.Zozulya Weidenfeller, Emilie Jaquiéry, 2014. Final results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with RR-MS (SWISSASCENT) [cited 2020 Nov 11]. Available from: https://onlinelibrary.ectrims-congress.eu/ectrims/2014/ACTRIMS-ECTRIMS2014/64498/adam.czaplinski.final.results.of.the.swiss.post.marketing.surveillance.html.
2. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group;Bates;JAMA,1995
3. Alemtuzumab-induced lung injury in multiple sclerosis: learning from adversity in three patients;Bianco;Mult. Scler. Relat. Disord.,2020
4. Alemtuzumab-induced halo naevus-like hypopigmentation - new insights into secondary skin autoimmunity in response to an immune cell-depleting antibody;Böhm;J. Eur. Acad. Dermatol. Venereol.,2020
5. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial;Cohen;The Lancet,2012
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献